BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 20228274)

  • 1. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.
    Wang GP; Berry CC; Malani N; Leboulch P; Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Bushman FD
    Blood; 2010 Jun; 115(22):4356-66. PubMed ID: 20228274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.
    Deichmann A; Hacein-Bey-Abina S; Schmidt M; Garrigue A; Brugman MH; Hu J; Glimm H; Gyapay G; Prum B; Fraser CC; Fischer N; Schwarzwaelder K; Siegler ML; de Ridder D; Pike-Overzet K; Howe SJ; Thrasher AJ; Wagemaker G; Abel U; Staal FJ; Delabesse E; Villeval JL; Aronow B; Hue C; Prinz C; Wissler M; Klanke C; Weissenbach J; Alexander I; Fischer A; von Kalle C; Cavazzana-Calvo M
    J Clin Invest; 2007 Aug; 117(8):2225-32. PubMed ID: 17671652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
    Cavazzana M; Six E; Lagresle-Peyrou C; André-Schmutz I; Hacein-Bey-Abina S
    Hum Gene Ther; 2016 Feb; 27(2):108-16. PubMed ID: 26790362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retroviral integration and human gene therapy.
    Bushman FD
    J Clin Invest; 2007 Aug; 117(8):2083-6. PubMed ID: 17671645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
    Davé UP; Akagi K; Tripathi R; Cleveland SM; Thompson MA; Yi M; Stephens R; Downing JR; Jenkins NA; Copeland NG
    PLoS Genet; 2009 May; 5(5):e1000491. PubMed ID: 19461887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo.
    Schwarzwaelder K; Howe SJ; Schmidt M; Brugman MH; Deichmann A; Glimm H; Schmidt S; Prinz C; Wissler M; King DJ; Zhang F; Parsley KL; Gilmour KC; Sinclair J; Bayford J; Peraj R; Pike-Overzet K; Staal FJ; de Ridder D; Kinnon C; Abel U; Wagemaker G; Gaspar HB; Thrasher AJ; von Kalle C
    J Clin Invest; 2007 Aug; 117(8):2241-9. PubMed ID: 17671654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotoxicity of retroviral hematopoietic stem cell gene therapy.
    Trobridge GD
    Expert Opin Biol Ther; 2011 May; 11(5):581-93. PubMed ID: 21375467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus.
    Beard BC; Keyser KA; Trobridge GD; Peterson LJ; Miller DG; Jacobs M; Kaul R; Kiem HP
    Hum Gene Ther; 2007 May; 18(5):423-34. PubMed ID: 17518616
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Rajawat YS; Humbert O; Cook SM; Radtke S; Pande D; Enstrom M; Wohlfahrt ME; Kiem HP
    Hum Gene Ther; 2021 Jan; 32(1-2):113-127. PubMed ID: 32741228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.
    Wu C; Dunbar CE
    Front Med; 2011 Dec; 5(4):356-71. PubMed ID: 22198747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parachuting in the epigenome: the biology of gene vector insertion profiles in the context of clinical trials.
    Baum C
    EMBO Mol Med; 2011 Feb; 3(2):75-7. PubMed ID: 21254403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns.
    Laufs S; Nagy KZ; Giordano FA; Hotz-Wagenblatt A; Zeller WJ; Fruehauf S
    Mol Ther; 2004 Nov; 10(5):874-81. PubMed ID: 15509505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.
    Cooper AR; Lill GR; Shaw K; Carbonaro-Sarracino DA; Davila A; Sokolic R; Candotti F; Pellegrini M; Kohn DB
    Blood; 2017 May; 129(19):2624-2635. PubMed ID: 28351939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector.
    Horino S; Uchiyama T; So T; Nagashima H; Sun SL; Sato M; Asao A; Haji Y; Sasahara Y; Candotti F; Tsuchiya S; Kure S; Sugamura K; Ishii N
    PLoS One; 2013; 8(8):e71594. PubMed ID: 23990961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells.
    Calmels B; Ferguson C; Laukkanen MO; Adler R; Faulhaber M; Kim HJ; Sellers S; Hematti P; Schmidt M; von Kalle C; Akagi K; Donahue RE; Dunbar CE
    Blood; 2005 Oct; 106(7):2530-3. PubMed ID: 15933056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.
    Aiuti A; Cassani B; Andolfi G; Mirolo M; Biasco L; Recchia A; Urbinati F; Valacca C; Scaramuzza S; Aker M; Slavin S; Cazzola M; Sartori D; Ambrosi A; Di Serio C; Roncarolo MG; Mavilio F; Bordignon C
    J Clin Invest; 2007 Aug; 117(8):2233-40. PubMed ID: 17671653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency.
    Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Adams S; Howe SJ; Al Ghonaium A; Bayford J; Brown L; Davies EG; Kinnon C; Thrasher AJ
    Sci Transl Med; 2011 Aug; 3(97):97ra79. PubMed ID: 21865537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curing genetic disease with gene therapy.
    Williams DA
    Trans Am Clin Climatol Assoc; 2014; 125():122-8; discussion 128-9. PubMed ID: 25125725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency.
    van der Loo JC; Swaney WP; Grassman E; Terwilliger A; Higashimoto T; Schambach A; Hacein-Bey-Abina S; Nordling DL; Cavazzana-Calvo M; Thrasher AJ; Williams DA; Reeves L; Malik P
    Gene Ther; 2012 Aug; 19(8):872-6. PubMed ID: 22551777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.
    Hacein-Bey-Abina S; Pai SY; Gaspar HB; Armant M; Berry CC; Blanche S; Bleesing J; Blondeau J; de Boer H; Buckland KF; Caccavelli L; Cros G; De Oliveira S; Fernández KS; Guo D; Harris CE; Hopkins G; Lehmann LE; Lim A; London WB; van der Loo JC; Malani N; Male F; Malik P; Marinovic MA; McNicol AM; Moshous D; Neven B; Oleastro M; Picard C; Ritz J; Rivat C; Schambach A; Shaw KL; Sherman EA; Silberstein LE; Six E; Touzot F; Tsytsykova A; Xu-Bayford J; Baum C; Bushman FD; Fischer A; Kohn DB; Filipovich AH; Notarangelo LD; Cavazzana M; Williams DA; Thrasher AJ
    N Engl J Med; 2014 Oct; 371(15):1407-17. PubMed ID: 25295500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.